市場調査レポート
商品コード
1127667

遺伝子治療の研究開発の世界市場(2022年~2032年)

Gene Therapy R&D Market Report 2022-2032

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 461 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=195.22円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

遺伝子治療の研究開発の世界市場(2022年~2032年)
出版日: 2022年09月15日
発行: Visiongain Reports Ltd.
ページ情報: 英文 461 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の遺伝子治療の研究開発の市場規模は、2021年に16億5,300万米ドルとなり、予測期間(2022年~2032年)にCAGR30.1%で成長すると予測されています。地域別では、アジア太平洋が先進医療用医薬品の中心地であり続けると予測されています。同地域では、イノベーション、研究、開発を促進するために各国政府が多くの立法措置を講じていることから、予測期間中の市場拡大の促進が見込まれています。

当レポートでは、世界の遺伝子治療の研究開発市場について調査し、市場規模や予測、市場力学、セグメント・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
  • 促進要因
  • 抑制要因・課題
  • 機会
  • COVID-19影響分析
  • ポーターのファイブフォース分析
  • PEST分析
  • パイプライン分析

第4章 疾患別:遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 疾患セグメントの成長見通し
  • 疾患別:遺伝子治療研究開発の市場規模推計・予測
  • がん
  • 希少疾患
  • 心血管疾患
  • 眼科疾患
  • 血液
  • 神経
  • 糖尿病
  • その他の疾患

第5章 ベクター別:遺伝子治療の研究開発市場分析

  • 主な調査結果
  • ベクターセグメントの成長見通し
  • ベクター別:遺伝子治療研究開発の市場規模推計・予測
  • ウイルス性
  • 非ウイルス性

第6章 技術別:遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 技術セグメントの成長見通し
  • 技術別:遺伝子治療研究開発の市場規模推計・予測
  • 遺伝子増強療法
  • 遺伝子補充療法

第7章 参入企業別:遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 参入企業セグメントの成長見通し
  • 参入企業別:遺伝子治療研究開発の市場規模推計・予測
  • 中小規模の製薬およびバイオテクノロジー
  • 大学・調査機関
  • 病院、政府、公共団体
  • 大手製薬会社

第8章 地域別:遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 地域の市場規模推計・予測
  • COVID-19影響分析:回復シナリオ(V、U、W、L)

第9章 北米の遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 市場魅力指数
  • 市場規模:国別(金額、2022年、2027年、2032年)
  • 市場規模推計・予測:国別(金額、2022年~2032年)
  • 市場規模推計・予測:疾患別(金額、2022年~2032年)
  • 市場規模推計・予測:ベクター別(金額、2022年~2032年)
  • 市場規模推計・予測:技術別(金額、2022年~2032年)
  • 市場規模推計・予測:参入企業別(金額、2022年~2032年)
  • 米国
  • カナダ

第10章 欧州の遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 市場魅力指数
  • 市場規模:国別(金額、2022年、2027年、2032年)
  • 市場規模推計・予測:国別(金額、2022年~2032年)
  • 市場規模推計・予測:疾患別(金額、2022年~2032年)
  • 市場規模推計・予測:ベクター別(金額、2022年~2032年)
  • 市場規模推計・予測:技術別(金額、2022年~2032年)
  • 市場規模推計・予測:参入企業別(金額、2022年~2032年)
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • ロシア
  • その他欧州

第11章 アジア太平洋の遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 市場魅力指数
  • 市場規模:国別(金額、2022年、2027年、2032年)
  • 市場規模推計・予測:国別(金額、2022年~2032年)
  • 市場規模推計・予測:疾患別(金額、2022年~2032年)
  • 市場規模推計・予測:ベクター別(金額、2022年~2032年)
  • 市場規模推計・予測:技術別(金額、2022年~2032年)
  • 市場規模推計・予測:参入企業別(金額、2022年~2032年)
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • 東南アジア
  • その他アジア太平洋地域

第12章 ラテンアメリカの遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 市場魅力指数
  • 市場規模:国別(金額、2022年、2027年、2032年)
  • 市場規模推計・予測:国別(金額、2022年~2032年)
  • 市場規模推計・予測:疾患別(金額、2022年~2032年)
  • 市場規模推計・予測:ベクター別(金額、2022年~2032年)
  • 市場規模推計・予測:技術別(金額、2022年~2032年)
  • 市場規模推計・予測:参入企業別(金額、2022年~2032年)
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ

第13章 中東・アフリカの遺伝子治療の研究開発市場分析

  • 主な調査結果
  • 市場魅力指数
  • 市場規模:国別(金額、2022年、2027年、2032年)
  • 市場規模推計・予測:国別(金額、2022年~2032年)
  • 市場規模推計・予測:疾患別(金額、2022年~2032年)
  • 市場規模推計・予測:ベクター別(金額、2022年~2032年)
  • 市場規模推計・予測:技術別(金額、2022年~2032年)
  • 市場規模推計・予測:参入企業別(金額、2022年~2032年)
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第14章 企業プロファイル

  • 遺伝子治療の研究開発における成功のための戦略の選択
  • 2021年3月現在、承認されている細胞治療・遺伝子治療製品
  • 企業別遺伝子治療臨床試験の実施状況
  • 遺伝子治療企業の資本化
  • 戦略的展望
  • Astellas Pharma Inc.
  • American Gene Technologies
  • Applied Genetic
  • Bayer
  • Benitec BioPharma
  • Biogen
  • Bluebird Bio
  • Bristol Myers Squibb
  • Calimmune, Inc.(CSL Behiring)
  • Cellectis
  • F. Hoffmann-La Roche Ltd.
  • GenSight Biologics
  • Gilead Lifesciences, Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Oxford Biomedica
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Spark Therapeutics(Subsidiary of Roche)
  • Takeda Pharmaceuticals
  • Transgene
  • UniQure NV
  • Voyager Therapeutics
  • ViGeneron
  • GeneQuine Biotherapeutics
  • OCUGEN, INC.
  • Taysha GTx
  • Sarepta Therapeutics, Inc.

第15章 結論と提言

  • 結論
  • 市場関係者への提言
図表

List of Tables

  • Table 1 Gene Therapy R&D Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
  • Table 2 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Gene Therapy Pipeline: Q1-Q4, 2022
  • Table 7 Gene Therapy Pipeline: Q1-Q4, 2023
  • Table 8 Gene Therapy Pipeline: Q1-Q4, 2024
  • Table 9 Gene Therapy Pipeline: Q1-Q4, 2025
  • Table 10 Gene Therapy Pipeline Assets Forecast till 2026 (US$ mn)
  • Table 11 Global Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 12 Cancer Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR %)
  • Table 13 Rare Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 14 Global Gene Therapy R&D Market Forecast by Rare Diseases, 2022-2032 (US$ mn, AGR%, CAGR %)
  • Table 15 Cardiovascular Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 16 Ophthalmic Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 17 Hematology Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 18 Neurological Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 19 Diabetes Mellitus Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 20 Other Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 21 Global Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 22 Viral Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 23 Global Gene Therapy R&D Market Forecast by Viral Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 24 Viral Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 25 Global Gene Therapy R&D Market Forecast by Non-viral, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 26 Global Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 27 Gene Augmentation Therapy Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 28 Gene Replacement Therapy Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 29 Global Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 30 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 31 Universities & Research Institutes Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 32 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 33 Big Pharma Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 34 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 35 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 36 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 37 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 38 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 39 North America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR %)
  • Table 40 North America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 41 North America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 42 North America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 43 North America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 44 U.S. Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 45 Canada Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 46 Europe Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 47 Europe Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR %)
  • Table 48 Europe Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 49 Europe Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 50 Europe Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 51 Germany Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 52 UK Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 53 France Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 54 Italy Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 55 Spain Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 56 Russia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 57 Rest of Europe Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR %)
  • Table 58 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 59 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 60 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 61 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 62 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 63 Japan Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR %)
  • Table 64 China Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 65 India Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 66 Australia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 67 South Korea Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 68 South East Asia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 69 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 70 Latin America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 71 Latin America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 72 Latin America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 73 Latin America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 74 Latin America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 75 Brazil Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 76 Mexico Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 77 Rest of Latin America Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 78 MEA Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR %)
  • Table 79 MEA Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 80 MEA Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 81 MEA Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 82 MEA Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 83 GCC Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 84 South Africa Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 85 Rest of MEA Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
  • Table 86 Gene Therapy R&D Market Strategic Outlook
  • Table 87 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Astellas Pharma Inc.: Product Benchmarking
  • Table 89 American Gene Technologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 American Gene Technologies: Product Benchmarking
  • Table 91 Applied Genetic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Applied Genetic: Product Benchmarking
  • Table 93 Applied Genetic: Strategic Outlook
  • Table 94 Bayer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Bayer: Product Benchmarking
  • Table 96 Bayer: Strategic Outlook
  • Table 97 Benitec BioPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Benitec BioPharma: Product Benchmarking
  • Table 99 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Biogen: Product Benchmarking
  • Table 101 Biogen: Strategic Outlook
  • Table 102 Bluebird Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Bluebird Bio: Product Benchmarking
  • Table 104 Bluebird Bio: Strategic Outlook
  • Table 105 Bristol Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Bristol Myers Squibb: Product Benchmarking
  • Table 107 Bristol Myers Squibb: Strategic Outlook
  • Table 108 Calimmune, Inc. (CSL Behiring): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 Calimmune, Inc. (CSL Behiring): Product Benchmarking
  • Table 110 Calimmune, Inc. (CSL Behiring): Strategic Outlook
  • Table 111 Cellectis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Cellectis: Product Benchmarking
  • Table 113 Cellectis: Strategic Outlook
  • Table 114 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 F. Hoffmann-La Roche Ltd.: Product Benchmarking
  • Table 116 F. Hoffmann-La Roche Ltd.: Strategic Outlook
  • Table 117 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 GenSight Biologics: Product Benchmarking
  • Table 119 Gilead Lifesciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 Gilead Lifesciences, Inc.: Product Benchmarking
  • Table 121 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Novartis AG: Product Benchmarking
  • Table 123 Novartis AG: Strategic Outlook
  • Table 124 Orchard Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 Orchard Therapeutics: Product Benchmarking
  • Table 126 Orchard Therapeutics: Strategic Outlook
  • Table 127 Oxford Biomedica: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128 Oxford Biomedica: Product Benchmarking
  • Table 129 Oxford Biomedica: Strategic Outlook
  • Table 130 Pfizer, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 Pfizer, Inc.: Product Benchmarking
  • Table 132 Pfizer, Inc.: Strategic Outlook
  • Table 133 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 134 REGENXBIO Inc.: Product Benchmarking
  • Table 135 REGENXBIO Inc.: Strategic Outlook
  • Table 136 Sangamo Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Sangamo Therapeutics, Inc.: Product Benchmarking
  • Table 138 Sangamo Therapeutics, Inc.: Strategic Outlook
  • Table 139 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 140 Sanofi: Product Benchmarking
  • Table 141 Sanofi: Strategic Outlook
  • Table 142 Spark Therapeutics (Subsidiary of Roche): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Spark Therapeutics (Subsidiary of Roche): Product Benchmarking
  • Table 144 Spark Therapeutics (Subsidiary of Roche): Strategic Outlook
  • Table 145 Takeda Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Takeda Pharmaceuticals: Product Benchmarking
  • Table 147 Takeda Pharmaceuticals: Strategic Outlook
  • Table 148 Transgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 149 Transgene: Product Benchmarking
  • Table 150 UniQure NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 151 UniQure NV: Product Benchmarking
  • Table 152 UniQure NV: Strategic Outlook
  • Table 153 Voyager Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 154 Voyager Therapeutics: Product Benchmarking
  • Table 155 Voyager Therapeutics: Strategic Outlook
  • Table 156 ViGeneron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 157 ViGeneron: Product Benchmarking
  • Table 158 ViGeneron: Strategic Outlook
  • Table 159 GeneQuine Biotherapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 160 GeneQuine Biotherapeutics: Product Benchmarking
  • Table 161 GeneQuine Biotherapeutics: Strategic Outlook
  • Table 162 OCUGEN, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 163 OCUGEN, INC.: Product Benchmarking
  • Table 164 OCUGEN, INC.: Strategic Outlook
  • Table 165 Taysha GTx: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 166 Taysha GTx: Product Benchmarking
  • Table 167 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 168 Sarepta Therapeutics, Inc.: Product Benchmarking
  • Table 169 Sarepta Therapeutics, Inc.: Strategic Outlook

List of Figures

  • Figure 1 Gene Therapy R&D Market Segmentation
  • Figure 2 Gene Therapy R&D Market by Disease: Market Attractiveness Index
  • Figure 3 Gene Therapy R&D Market by Vector: Market Attractiveness Index
  • Figure 4 Gene Therapy R&D Market by Techniques: Market Attractiveness Index
  • Figure 5 Gene Therapy R&D Market by Participants: Market Attractiveness Index
  • Figure 6 Gene Therapy R&D Market Attractiveness Index by Region
  • Figure 7 Gene Therapy R&D Market: Market Dynamics
  • Figure 8 Gene, Cell & Tissue Bases Therapeutic Developers Financings by Deal Type, 2021
  • Figure 9 Gene, Cell & Tissue Bases Therapeutic Developers Financings by Deal Type, 2020
  • Figure 10 Rare vs. Prevalent: Industry Sponsored Trials
  • Figure 11 Rare vs. Prevalent: Academic & Government Sponsored Trials
  • Figure 12 COVID Impact Analysis: Gene Therapy R&D Market Recovery Scenarios
  • Figure 13 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "V" Shaped Recovery
  • Figure 14 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "U" Shaped Recovery
  • Figure 15 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "W" Shaped Recovery
  • Figure 16 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "L" Shaped Recovery
  • Figure 17 Gene Therapy R&D Marke
目次
Product Code: PHA1188

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

“The Gene Therapy R&D Market Report 2022-2032”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Diversification of Technical Risks is a Key Strategy for Winning in the Gene Therapy R&D Market

The majority of the biotechnology firms associated with gene therapies are established across a special technology platform i.e., novel viral capsid that could have favoured acceptance in an organ system. Most of them continue to de-risk the technology as soon as possible, with the underlying technology platform that gave birth to the gene therapy candidates often being the main feature across chosen indications. This focuses risk on the technology platform & exposes the company to a catastrophic event that would have a negative impact on the entire portfolio. When it comes to this challenge, early-stage gene therapy firms often lack this choice; and once the newly founded technology achieves traction, executives will often follow adjacent plans that diversify risk & optimize prospects for the company. Companies working on gene therapies may evolve distinct viral delivery vectors or technologies for in vivo & ex vivo applications. Furthermore, balancing spending levels between developed and emerging channels, as well as deciding whether to implement new innovations in-house or obtain them from outside sources, is difficult. Importantly, strategic decisions about technology should be matched with strategic decisions about indication mix to ensure a clear future path.

400 million People Suffer from One or More of Over 7,000 Rare Diseases

About 400 million people globally suffer from one or more of over 7,000 rare diseases reported. Rare disease affects between 3.5% and 5.9% of the world's population. The cause of 72% of rare diseases is hereditary, while others are triggered by pathogens (bacterial or viral), asthma, and environmental conditions, or are degenerative and proliferative in nature. Approximately, 70% of genetic rare diseases begin in childhood. Symptoms that are relatively normal can obscure underlying unusual disorders, resulting in misdiagnosis and treatment delays. The lack of loss of mobility caused by the chronic, worsening, degenerative, and often life-threatening manifestations of the condition has a significant effect on the patient's quality of life. Thus, the rising number of rare disease patients around the world is anticipated to drive the gene therapy application in this segment during the forecast period.

The costliest medication in the world right now is Zolgensma, which treats spinal muscular atrophy, a rare hereditary illness that harms nerve cells and causes muscle degeneration. The life-saving medication's one-time treatment for a young child costs $2.1 million. While Zolgensma's excessive cost is an incongruity at present times, there will be several cell & gene therapies available over the next ten years, with prices ranging from thousands to millions of dollars for a single dose. By 2025, the FDA is anticipated to approve 10-20 cell & gene therapies annually.

Asia-Pacific Region Remains a Hub for Advanced Therapy Medicinal Products

With the many legislative initiatives put forth by the governments to promote innovation, research, and development in Asia-Pacific, the area remains a hub for advanced therapy medicinal products. Over the course of the projected period, this is expected to propel market expansion. A*STAR's Bioprocessing Technology Institute (BTI) and WuXi Advanced Therapies, a fully owned subsidiary of WuXi AppTec, established a new agreement in May 2022 to introduce WuXi ATU's unique Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology in the Asia-Pacific area. WuXi ATU will provide the resources, tools, funds, and training necessary to advance the development and commercialization of TESSA technology in Singapore as part of this partnership. BTI will support WuXi ATU in its research and development of cell and gene therapy in Singapore by providing research skills, facilities, and access to its network of partners.

What Are These Questions You Should Ask Before Buying A Market Research Report?

  • How is the gene therapy R&D market evolving?
  • What is driving and restraining the gene therapy R&D market?
  • How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each gene therapy R&D submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the gene therapy R&D projects for these leading companies?
  • How will the industry evolve during the period between 2022 and 2032? What are the implication of gene therapy R&D projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
  • Where is the gene therapy R&D market heading? And how can you ensure you are at the forefront of the market?
  • What can be the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path? C-suite?

You need to discover how this will impact the Gene Therapy R&D Market today, and over the next 10 years:

  • Our 461-page report provides 169 tables and 228 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • Contains in-depth analysis of global, regional and national sales and growth
  • Highlights for you the key successful trends, changes and revenue projections made by your competitors

This report tells you TODAY how the Gene Therapy R&D Market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), PEST analysis, Porter's Five Forces and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U' are discussed in this report.

Segments Covered in the Report:

Disease

  • Cancer
  • Rare Diseases
    • Oncologic
    • Non-oncologic
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Haematology
  • Neurological
  • Diabetes Mellitus
  • Other Diseases

Vector

  • Viral
    • Retrovirus
    • Adenovirus
    • AAV
    • Lentivirus
    • Others
  • Non-viral
    • Naked DNA
    • Gene Gun
    • Electroporation
    • Lipofection

Techniques

  • Gene Augmentation Therapy
  • Gene Replacement Therapy

Participants

  • Small/Medium Pharma & Biotech
  • Universities & Research Institutes
  • Hospitals
  • Government & Public Bodies
  • Big Pharma

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Gene Therapy R&D Market, 2022 to 2032, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

  • Astellas Pharma Inc.
  • American Gene Technologies
  • Applied Genetic
  • Bayer
  • Benitec BioPharma
  • Biogen
  • Bluebird Bio
  • Bristol Myers Squibb
  • Calimmune, Inc. (CSL Behiring)
  • Cellectis
  • F. Hoffmann-La Roche Ltd.
  • GeneQuine Biotherapeutics
  • GenSight Biologics
  • Gilead Lifesciences, Inc.
  • Novartis AG
  • OCUGEN, INC.
  • Orchard Therapeutics
  • Oxford Biomedica
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Sarepta Therapeutics, Inc.
  • Spark Therapeutics (Subsidiary of Roche)
  • Takeda Pharmaceuticals
  • Taysha GTx
  • Transgene
  • UniQure NV
  • Voyager Therapeutics
  • ViGeneron.

Overall world revenue for Gene Therapy R&D Market, 2022 to 2032 in terms of value the market will surpass US$2,126.3 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Gene Therapy R&D Market, 2022 to 2032 Market report helps you?

In summary, our 460+ page report provides you with the following knowledge:

  • Revenue forecasts to 2032 for Gene Therapy R&D Market, 2022 to 2032 Market, with forecasts for disease, vector, techniques, and participants size each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2032 for 5 regional and 18 key national markets - See forecasts for the Gene Therapy R&D Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market- including company profiles for 30 of the major companies involved in the Gene Therapy R&D Market, 2022 to 2032 Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Gene Therapy R&D Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Gene Therapy R&D Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered By This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Drivers
    • 3.3.1 Robust Gene Therapy Pipeline to Boost Growth
    • 3.3.2 Technological Advancements to Fuel Market Growth
    • 3.3.3 Increasing Investments by Major Players
      • 3.3.3.1 Financings by Deal Type, 2021
      • 3.3.3.2 Financings by Deal Type, 2020
    • 3.3.4 Growing Prevalence of Targeted Diseases Treatment
  • 3.4 Restraints/Challenges
    • 3.4.1 Cell & Gene Therapies Target Specific Diseases
    • 3.4.2 High Cost to Stifle Gene Therapy R&D Growth
    • 3.4.3 Regulatory Scenarios to Challenge Industry Growth
  • 3.5 Opportunities
    • 3.5.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
    • 3.5.2 Facility Expansion Anticipated to Offer Lucrative Growth Prospects
  • 3.6 COVID-19 Impact Analysis
  • 3.7 Porter's Five Forces Analysis
    • 3.7.1 Bargaining Power of Suppliers
    • 3.7.2 Bargaining Power of Buyers
    • 3.7.3 Competitive Rivalry
    • 3.7.4 Threat of Substitute Products
    • 3.7.5 Threat of New Entrants
  • 3.8 PEST Analysis
    • 3.8.1 Political Factors Impacting Gene Therapy R&D Market
    • 3.8.2 Economic Factors Impacting Gene Therapy R&D Market
    • 3.8.3 Social Factors Impacting Gene Therapy R&D Market
    • 3.8.4 Technological Factors Impacting Gene Therapy R&D Market
  • 3.9 Pipeline Analysis
    • 3.9.1 Projected Launch Year, 2022
    • 3.9.2 Projected Launch Year, 2023
    • 3.9.3 Projected Launch Year, 2024
    • 3.9.4 Projected Launch Year, 2025
    • 3.9.5 Gene Therapy Pipeline Assets Forecast till 2026
    • 3.9.6 Clinical Trials Activity by Key Areas
      • 3.9.6.1 Industry Sponsored Trials by Phase
      • 3.9.6.2 Academic and Government Sponsored Trials by Phase
      • 3.9.6.3 Rare Diseases Clinical Activity by Indication
      • 3.9.6.4 Prevalent Diseases Clinical Activity by Indication
      • 3.9.6.5 Next-Gen Therapies Competition by Region
      • 3.9.6.6 Indications With Significant Clinical Activity

4 Gene Therapy R&D Market Analysis by Disease

  • 4.1 Key Findings
  • 4.2 Disease Segment Growth Prospects
  • 4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 4.4 Cancer
    • 4.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.4.2 Market Share by Region, 2022 & 2032 (%)
  • 4.5 Rare Diseases
    • 4.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.5.2 Market Share by Region, 2022 & 2032 (%)
    • 4.5.3 Rare Diseases Segment Market Forecast by Type, 2022-2032 (US$ Mn)
  • 4.6 Cardiovascular Diseases
    • 4.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.6.2 Market Share by Region, 2022 & 2032 (%)
  • 4.7 Ophthalmic Diseases
    • 4.7.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.7.2 Market Share by Region, 2022 & 2032 (%)
  • 4.8 Hematology
    • 4.8.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.8.2 Market Share by Region, 2022 & 2032 (%)
  • 4.9 Neurological
    • 4.9.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.9.2 Market Share by Region, 2022 & 2032 (%)
  • 4.10 Diabetes Mellitus
    • 4.10.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.10.2 Market Share by Region, 2022 & 2032 (%)
  • 4.11 Other Diseases
    • 4.11.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 4.11.2 Market Share by Region, 2022 & 2032 (%)

5 Gene Therapy R&D Market Analysis by Vector

  • 5.1 Key Findings
  • 5.2 Vector Segment Growth Prospects
  • 5.3 Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 5.4 Viral
    • 5.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 5.4.2 Market Share by Region, 2022 & 2032 (%)
    • 5.4.3 Viral Segment Market Forecast by Type, 2022-2032 (US$ Mn)
      • 5.4.3.1 Retrovirus
      • 5.4.3.2 Adenovirus
      • 5.4.3.3 AAV (Adeno-Associated Virus)
      • 5.4.3.4 Lentivirus
      • 5.4.3.5 Others
  • 5.5 Non-viral
    • 5.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 5.5.2 Market Share by Region, 2022 & 2032 (%)
    • 5.5.3 Non-viral Segment Market Forecast by Type, 2022-2032 (US$ Mn)
      • 5.5.3.1 Naked DNA
      • 5.5.3.2 Gene Gun
      • 5.5.3.3 Electroporation
      • 5.5.3.4 Lipofection

6 Gene Therapy R&D Market Analysis by Techniques

  • 6.1 Key Findings
  • 6.2 Techniques Segment Growth Prospects
  • 6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 6.4 Gene Augmentation Therapy
    • 6.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 6.4.2 Market Share by Region, 2022 & 2032 (%)
  • 6.5 Gene Replacement Therapy
    • 6.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 6.5.2 Market Share by Region, 2022 & 2032 (%)

7 Gene Therapy R&D Market Analysis by Participants

  • 7.1 Key Findings
  • 7.2 Participants Segment Growth Prospects
  • 7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 7.4 Small/Medium Pharma & Biotech
    • 7.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 7.4.2 Market Share by Region, 2022 & 2032 (%)
  • 7.5 Universities & Research Institutes
    • 7.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 7.5.2 Market Share by Region, 2022 & 2032 (%)
  • 7.6 Hospitals, Government & Public Bodies
    • 7.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 7.6.2 Market Share by Region, 2022 & 2032 (%)
  • 7.7 Big Pharma
    • 7.7.1 Market Forecast by Region, 2022-2032 (US$ Mn)
    • 7.7.2 Market Share by Region, 2022 & 2032 (%)

8 Gene Therapy R&D Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast
  • 8.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)

9 North America Gene Therapy R&D Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Gene Therapy R&D Market Attractiveness Index
  • 9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
  • 9.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
  • 9.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
  • 9.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
  • 9.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
  • 9.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
  • 9.9 U.S.
  • 9.10 Canada

10 Europe Gene Therapy R&D Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Gene Therapy R&D Market Attractiveness Index
  • 10.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
  • 10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
  • 10.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
  • 10.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
  • 10.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
  • 10.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
  • 10.9 Germany
  • 10.10 UK
  • 10.11 France
  • 10.12 Italy
  • 10.13 Spain
  • 10.14 Russia
  • 10.15 Rest of Europe

11 Asia Pacific Gene Therapy R&D Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index
  • 11.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
  • 11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
  • 11.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
  • 11.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
  • 11.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
  • 11.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
  • 11.9 Japan
  • 11.10 China
  • 11.11 India
  • 11.12 Australia
  • 11.13 South Korea
  • 11.14 South East Asia
  • 11.15 Rest of Asia Pacific

12 Latin America Gene Therapy R&D Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Gene Therapy R&D Market Attractiveness Index
  • 12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
  • 12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
  • 12.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
  • 12.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
  • 12.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
  • 12.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
  • 12.9 Brazil
  • 12.10 Mexico
  • 12.11 Rest of Latin America

13 MEA Gene Therapy R&D Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Gene Therapy R&D Market Attractiveness Index
  • 13.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
  • 13.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
  • 13.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn)
  • 13.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn)
  • 13.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn)
  • 13.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn)
  • 13.9 GCC
  • 13.10 South Africa
  • 13.11 Rest of MEA

14 Company Profiles

  • 14.1 Strategic Choices for Winning in Gene Therapy R&D Market
    • 14.1.1 Diversification of Technical Risks
    • 14.1.2 How to Achieve Long Term Benefits to Patients
    • 14.1.3 Building Digital Capabilities
    • 14.1.4 Mergers & Acquisitions to Offer Lucrative Growth Prospects for Players Across the Value Chain
  • 14.2 Approved Cellular & Gene Therapy Products as of March 2021
  • 14.3 Ongoing Gene Therapy Clinical Trials by Companies
  • 14.4 Gene Therapy Companies Market Capitalization
  • 14.5 Strategic Outlook
  • 14.6 Astellas Pharma Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2015-2021
      • 14.6.3.2 Regional Market Shares, 2020
      • 14.6.3.3 Gross Profit, 2015-2021
      • 14.6.3.4 R&D, 2015-2021
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 American Gene Technologies
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 Applied Genetic
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2015-2021
      • 14.8.3.2 Gross Profit, 2015-2021
      • 14.8.3.3 R&D, 2015-2021
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Bayer
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2015-2021
      • 14.9.3.2 Regional Market Shares, 2021
      • 14.9.3.3 Gross Profit, 2015-2021
      • 14.9.3.4 R&D, 2015-2021
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Benitec BioPharma
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2015-2021
      • 14.10.3.2 Gross Profit, 2015-2021
      • 14.10.3.3 R&D, 2015-2021
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Biogen
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2015-2021
      • 14.11.3.2 Regional Market Shares, 2021
      • 14.11.3.3 Gross Profit, 2015-2021
      • 14.11.3.4 R&D, 2015-2021
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 Bluebird Bio
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2015-2021
      • 14.12.3.2 Gross Profit, 2015-2019
      • 14.12.3.3 R&D, 2015-2021
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 Bristol Myers Squibb
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2015-2021
      • 14.13.3.2 Regional Market Shares, 2021
      • 14.13.3.3 Gross Profit, 2015-2021
      • 14.13.3.4 R&D, 2015-2021
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Calimmune, Inc. (CSL Behiring)
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
    • 14.14.4 Strategic Outlook
  • 14.15 Cellectis
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2015-2021
      • 14.15.3.2 Gross Profit, 2015-2021
      • 14.15.3.3 R&D, 2015-2021
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 F. Hoffmann-La Roche Ltd.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2015-2021
      • 14.16.3.2 Gross Profit, 2015-2021
      • 14.16.3.3 R&D, 2015-2021
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 GenSight Biologics
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Product Benchmarking
    • 14.17.4 Strategic Outlook
  • 14.18 Gilead Lifesciences, Inc.
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2015-2021
      • 14.18.3.2 Gross Profit, 2015-2021
      • 14.18.3.3 R&D, 2015-2021
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Novartis AG
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2015-2021
      • 14.19.3.2 Regional Market Shares, 2021
      • 14.19.3.3 Gross Profit, 2015-2021
      • 14.19.3.4 R&D, 2015-2021
    • 14.19.4 Product Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 Orchard Therapeutics
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Product Benchmarking
    • 14.20.4 Strategic Outlook
  • 14.21 Oxford Biomedica
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2015-2021
      • 14.21.3.2 Regional Market Shares, 2021
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook
  • 14.22 Pfizer, Inc.
    • 14.22.1 Company Snapshot
    • 14.22.2 Company Overview
    • 14.22.3 Financial Analysis
      • 14.22.3.1 Net Revenue, 2015-2021
      • 14.22.3.2 Regional Market Shares, 2021
      • 14.22.3.3 Gross Profit, 2015-2021
      • 14.22.3.4 R&D, 2015-2021
    • 14.22.4 Product Benchmarking
    • 14.22.5 Strategic Outlook
  • 14.23 REGENXBIO Inc.
    • 14.23.1 Company Snapshot
    • 14.23.2 Company Overview
    • 14.23.3 Financial Analysis
      • 14.23.3.1 Net Revenue, 2015-2021
      • 14.23.3.2 Gross Profit, 2015-2021
      • 14.23.3.3 R&D, 2015-2021
    • 14.23.4 Product Benchmarking
    • 14.23.5 Strategic Outlook
  • 14.24 Sangamo Therapeutics, Inc.
    • 14.24.1 Company Snapshot
    • 14.24.2 Company Overview
    • 14.24.3 Financial Analysis
      • 14.24.3.1 Net Revenue, 2015-2021
      • 14.24.3.2 Gross Profit, 2015-2021
      • 14.24.3.3 R&D, 2015-2021
    • 14.24.4 Product Benchmarking
    • 14.24.5 Strategic Outlook
  • 14.25 Sanofi
    • 14.25.1 Company Snapshot
    • 14.25.2 Company Overview
    • 14.25.3 Financial Analysis
      • 14.25.3.1 Net Revenue, 2015-2021
      • 14.25.3.2 Regional Market Shares, 2021
      • 14.25.3.3 Gross Profit, 2015-2021
      • 14.25.3.4 R&D, 2015-2021
    • 14.25.4 Product Benchmarking
    • 14.25.5 Strategic Outlook
  • 14.26 Spark Therapeutics (Subsidiary of Roche)
    • 14.26.1 Company Snapshot
    • 14.26.2 Company Overview
    • 14.26.3 Product Benchmarking
    • 14.26.4 Strategic Outlook
  • 14.27 Takeda Pharmaceuticals
    • 14.27.1 Company Snapshot
    • 14.27.2 Company Overview
    • 14.27.3 Financial Analysis
      • 14.27.3.1 Net Revenue, 2015-2021
      • 14.27.3.2 Regional Market Shares, 2021
      • 14.27.3.3 Gross Profit, 2015-2021
      • 14.27.3.4 R&D, 2015-2021
    • 14.27.4 Product Benchmarking
    • 14.27.5 Strategic Outlook
  • 14.28 Transgene
    • 14.28.1 Company Snapshot
    • 14.28.2 Company Overview
    • 14.28.3 Product Benchmarking
    • 14.28.4 Strategic Outlook
  • 14.29 UniQure NV
    • 14.29.1 Company Snapshot
    • 14.29.2 Company Overview
    • 14.29.3 Financial Analysis
      • 14.29.3.1 Net Revenue, 2015-2021
      • 14.29.3.2 Gross Profit, 2015-2021
      • 14.29.3.3 R&D, 2015-2021
    • 14.29.4 Product Benchmarking
    • 14.29.5 Strategic Outlook
  • 14.30 Voyager Therapeutics
    • 14.30.1 Company Snapshot
    • 14.30.2 Company Overview
    • 14.30.3 Financial Analysis
      • 14.30.3.1 Net Revenue, 2015-2021
      • 14.30.3.2 Gross Profit, 2015-2021
      • 14.30.3.3 R&D, 2015-2021
    • 14.30.4 Product Benchmarking
    • 14.30.5 Strategic Outlook
  • 14.31 ViGeneron
    • 14.31.1 Company Snapshot
    • 14.31.2 Company Overview
    • 14.31.3 Product Benchmarking
    • 14.31.4 Strategic Outlook
  • 14.32 GeneQuine Biotherapeutics
    • 14.32.1 Company Snapshot
    • 14.32.2 Company Overview
    • 14.32.3 Product Benchmarking
    • 14.32.4 Strategic Outlook
  • 14.33 OCUGEN, INC.
    • 14.33.1 Company Snapshot
    • 14.33.2 Company Overview
    • 14.33.3 Product Benchmarking
    • 14.33.4 Strategic Outlook
  • 14.34 Taysha GTx
    • 14.34.1 Company Snapshot
    • 14.34.2 Company Overview
    • 14.34.3 Product Benchmarking
    • 14.34.4 Strategic Outlook
  • 14.35 Sarepta Therapeutics, Inc.
    • 14.35.1 Company Snapshot
    • 14.35.2 Company Overview
    • 14.35.3 Product Benchmarking
    • 14.35.4 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from
  • 15.2 Recommendations for Market Players